RE: K-Ras 4601 _ Implication
Now that bigger drugs companies have identified K-ras as a biomarker for not giving Erbitux and V to their patients.
They will develop screening tests in order to identify positive K-ras patients.
That's actually great news for 4601 for 2 reasons:
1- K-Ras is now a niche market, recognized niche market
2- New testing and screening will help TLN identify their own subset of patients. Those test exist and are cheap.
This K-Ras discovery in itself reduced costs for 4601 and increase odds of success for 4601 in pancreatic and colon cancer. All this workd done by others!
The unknown pharma is probably uninterested in GBM.
Pancreatic, colon cancer will be targetted next.